Patents - stay tuned to the technology

Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Nitrogen containing other than solely as a nitrogen in an inorganic ion of an addition salt, a nitro or a nitroso DOAI

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514613000 Carboxamides (i.e., R-C(=O)-N, wherein R is a radical having carbon bonded directly to the C(=O)-N or is hydrogen and wherein any substituent attached to nitrogen will be referred to as E) 695
514646000 Benzene ring containing 537
514631000 Amidines (i.e., N=C-N) 137
514601000 Sulfonamides (i.e., Q-(O=)S(=O)-N, wherein Q is a substituent and wherein any substituent attached to the nitrogen will be referred to as E) 66
514588000 Ureas (i.e., N-C(=O)-N) 66
514642000 Quaternary ammonium containing 63
514663000 Acyclic 55
514660000 Plural alicyclic rings 48
514638000 Nitrogen double bonded directly to carbon 20
514599000 Thiocarboxamides, (i.e., C(=S)-N) 16
514580000 Thioureas (i.e., N-C(=S)-N 15
514659000 Alicyclic ring or ring system and amino nitrogen are attached indirectly by an acyclic carbon or acyclic chain 8
514600000 Sulfamides (i.e., N-(O=)S(=O)-N) 4
20090221710Acyclic Sulfamide Derivatives - The present invention is related to acyclic sulfamide derivatives, useful for the manufacture of a medicament for satiety induction and ingestion control, corporal fat modulation and lipidic metabolism regulation and for the manufacture of a medicament for the treatment or prevention of diabetes and cardiovascular diseases. The acyclic sulfamide derivatives are also useful for cosmetic use.09-03-2009
20100048712Acyclic Sulfamide Derivatives - The present invention is related to acyclic sulphamide derivatives of formula (I), wherein R02-25-2010
20100179224Acyclic Sulfamide Derivatives - The present invention is related to acyclic sulphamide derivatives of formula (I), wherein R07-15-2010
20140371319NOVEL INDANESULFAMlDE DERIVATIVES - Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.12-18-2014
514645000 Nitroxides, oxyamines or hydroxylamines (i.e., N-O or N-OH) 3
20090137683Anticancer effect enhancer - An object of the present invention is to provide an enhancing agent for effect of anticancer agent for achieving an excellent therapeutic effect on cancer. The enhancing agent for effect of anticancer agent according to the present invention which is a solving means therefor is characterized in that a nitric oxide donor is an effective ingredient. In accordance with the present invention, an excellent therapeutic effect is able to be achieved on non-small cell lung cancer which is still in such a state that no effective therapeutic method has been established yet for a progressive cancer which is not operable and is one of cancers where chemotherapy is most difficult to apply.05-28-2009
20100197799HYDROXYLAMINE DERIVATIVES - This invention is related to hydroxylamino derivatives of the following general formula (I)08-05-2010
20140148513SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME - The invention provides methods of inhibiting the development or progression of a thioesterase deficiency disorder in a mammal by the administration of a compound that functionally mimics the enzymatic activity of all thioesterases in mammals. Such thioesterase deficiency disorders include cancers and adult- or infant-neuronal ceroid lipofuscinoses (NCLs). The invention also provides small molecule mimics of thioesterases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds and methods of using the same.05-29-2014
514610000 Nitramines (i.e., compounds containing nitro bonded directly to amino nitrogen) 2
20090170951Phenolic Hydrazone Macrophage Migration Inhibitory Factor Inhibitors - Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.07-02-2009
20090270509NITRIC OXIDE-RELEASING MOLECULES - This invention relates to compositions comprising carbon-based diazeniumdiolates that release nitric oxide (NO). The carbon-based diazeniumdiolated molecules release NO spontaneously under physiological conditions without subsequent nitrosamine formation. The present invention also relates to methods of preparing the carbon-based diazeniumdiolated molecules, compositions comprising such molecules, methods of using such compositions, and devices employing such molecule compositions.10-29-2009
514609000 Cyanamides (i.e., compounds containing cyano bonded directly to amino nitrogen) 2
20100048713COMPOUNDS ACTING ON THE SEROTONIN TRANSPORTER - The invention relates to new chemical compounds acting on the serotonin transporter (SERT), and associated pharmaceutical compositions, methods for use as therapeutic agents, and methods of preparation thereof. In particular the new chemical compounds are useful for the treatment of a variety of central nervous system (CNS) disorders—for example anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, cognitive disorders, sleep disorders, feeding disorders, panic attacks, disorders related to withdrawl from drug abuse, schizophrenia, or the like, or in the treatment of gastrointestinal disorders such as irritable bowel syndrome.02-25-2010
20130190406PEST CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PEST - The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and the cyanamide compound represented by Formula (2) shows an excellent controlling activity on a pest.07-25-2013
514608000 Sulfur attached directly to amino nitrogen by nonionic bonding (e.g., sulfenamides, etc.) 2
20090258947NOVEL LOW DOSE PHARMACEUTICAL COMPOSITIONS COMPRISING NIMESULIDE, PREPARATION AND USE THEREOF - Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10-15-2009
20110028560SELF-EMULSIFIABLE LIQUID FLORFENICOL COMPOSITION INTENDED TO BE INCORPORATED INTO THE DRINKING WATER OF LIVESTOCK - The invention relates to a self-emulsifiable liquid composition intended to be diluted in an aqueous intermediate solution and then incorporated into the drinking water of livestock animals, and also to the use of such a composition. The invention is characterized in that the composition comprises at least—between 1% and 12% by weight of the florfenicol active ingredient, relative to the total volume of the composition; —at least 50% by weight, relative to the total volume of the composition (p/v), of a mixture of C8-C10 saturated polyglycosylated glycerides having an HLB (hydrophilic-lipophilic balance) of less than 16; and—at least 5% by weight, relative to the total volume of the composition (p/v), of a surfactant.02-03-2011
514612000 Haloamines (i.e., compounds containing halogen attached directly to amino nitrogen by nonionic bonding) 2
20110124734N-HALOGENATED AMINO ACID FORMULATIONS AND METHODS FOR CLEANING AND DISINFECTION - The present invention relates to methods for disinfecting or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid and a phase transfer agent for a time sufficient to disinfect or clean the lens. This specification further discloses a formulation for disinfecting a contact lens comprising an N-halogenated amino acid and a phase transfer agent.05-26-2011
20130231391ADAMANTANE DERIVATIVES POSSESSING ANTI-VIRAL AND ANTI-MICROBIAL ACTIVITY - The present invention relates to adamantane derivatives that are active as antiviral and anti-microbial agents; antiviral or antibacterial compositions comprising adamantane derivatives or pharmaceutically acceptable salts thereof; and methods of preventing or treating viral or bacterial infections in mammalian hosts through the administration of adamantine derivatives or their salts or pharmaceutical compositions comprising the same. In particular, viral infections prevented or treated by the methods of the present invention may include, but are not limited to, those caused by arenavirus or one or more pox viruses, such as vaccinia and/or variola.09-05-2013
514611000 Nitrosamines (i.e., compounds containing nitroso bonded directly to amino nitrogen) 1
20080300313Solvent Mixture for Preparing Water-Dilutable Liquid Concentrate Formulation of Organic Pesticide Compounds - The present invention relates to a solvent mixture SM for preparing a water-dilutable liquid concentrate formulation of sparingly soluble organic pesticide compounds C having a water solubilty of not more than 5 g/l at 25° C./1013 mbar. The present invention also relates to water-dilutable liquid concentrate formulation, which comprises said solvent mixture SM and at least one non-ionic surfactant.12-04-2008
514644000 Amine oxides 1
20090088481Method of Protecting Wood Through Enhanced Penetration of Wood Preservatives and a Related Solution - A method of protecting wood through enhanced penetration of wood preservatives includes providing a solution including (a) at least one amine oxide, (b) at least one organic wood preservative and (c) a buffering agent. The solution preferably has a pH of about 7 to 10. The solution is applied to the surface of the wood after which, with or without intervening storage, the materials are activated to effect enhanced penetration of the organic wood preservative into the wood. One may effect application at a solution temperature of about 30 to 75° C. and preferably about 50 to 60° C. to effect activation at a higher temperature and high relative humidity. In a preferred practice, the wood may be heated before and/or after application of the solution. The solution is also disclosed as a product.04-02-2009
Entries
DocumentTitleDate
20090197963Method and compositions for suppressing appetite or treating obesity - The present invention provides a method for reducing the appetite in a mammal by contacting the mammal with an amount of a noxious smelling agent effective in reducing appetite or by contacting the mammal with an agent effective in inhibiting the effect of another agent in stimulating appetite. Also, the present invention provides a method for treating obesity in a mammal by contacting the mammal with an amount of a noxious smelling agent effective in reducing appetite or with an agent effective in inhibiting the effect of another agent in stimulating appetite. Similarly, the present invention provides compositions and kits for both reducing appetite and treating obesity. In some instances, an isonitrile or an isocyanide is present in the composition or kit.08-06-2009
20100035995Compositions comprising Cyclohexylamines and Aminoadamantanes - The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.02-11-2010
201001977921-Amino-Alkylcyclohexane derivatives for the treatment of inflammatory skin diseases - The present invention relates to the treatment of an individual afflicted with inflammatory skin diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.08-05-2010
201002984401-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF HEARING LOSS - The present invention relates to the treatment of an individual diagnosed with hearing loss comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.11-25-2010
20100298441TITRATION PACKAGE FOR NERAMEXANE AND ITS USE IN THE TREATMENT OF AN INNER EAR DISORDER - The present invention relates to a titration scheme for the administration of a 1-amino-alkylcyclohexane derivative which allows for quick attainment of an effective dose of a 1-amino-alkylcyclohexane derivative while minimizing side effects. The present invention further relates to a titration package for providing a 1-amino-alkylcyclohexane derivative (e.g., neramexane or a pharmaceutically acceptable salt thereof) in at least two different dosages. The present titration scheme/titration package may be useful in the treatment of various diseases, including tinnitus.11-25-2010
201002984421-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists - Certain 1-aminoalkylcyclohexanes are systematically-active 5HT3 and nicotinic receptor antagonists and are useful in the inhibition of progression of or alleviation of conditions resulting from disturbances of serotoninergic or nicotinergic transmission giving them a wide range of utility in the treatment of CNS-disorders. Pharmaceutical compositions thereof for such purpose and method of making same, as well as a method-of-treating conditions which are alleviated by the employment of a 5HT3 or neuronal nicotinic receptor antagonist.11-25-2010
201100773041-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS. - The present invention relates to the treatment of an individual afflicted with cochlear tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.03-31-2011
20110092600PHARMACEUTICAL COMPOSITIONS COMPRISING AMINOCYCLOHEXANE DERIVATIVES - The present invention relates to pharmaceutical compositions comprising 1-aminocyclohexane derivatives and a cyclodextrin, which compositions exhibit advantageous safety, convenience, and dosing characteristics. The compositions of the instant invention find particular application in the treatment of various diseases and conditions of the CNS, including those involving the impairment of cognitive function or dementia, such as Alzheimer's disease.04-21-2011
201101781791-AMINO-ALKYLCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT IN TINNITUS - The present invention relates to the treatment of an individual afflicted with cognitive impairment associated with tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.07-21-2011
201102512831-AMINO-ALKYLCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF MAST CELL MEDIATED DISEASES - The present invention relates to the treatment of an individual afflicted with mast cell mediated diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.10-13-2011
20110294890Neramexane for the treatment or prevention of inner ear disorders - The present invention relates to a method of treatment or prevention of an inner ear disorder in a female comprising administering a therapeutically effective amount of neramexane or a pharmaceutically acceptable salt thereof to a female.12-01-2011
20120046365Method and Composition for Administering an NMDA Receptor Antagonist to a Subject - The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.02-23-2012
20120157537NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau - Aminocyclohexane and aminoalkylcyclohexane compounds, which are systemically-active as NMDA receptor antagonists, are effective in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau, method of treating disorders resulting from or associated with abnormal hyperphosphorylation of microtubule associated protein tau, and pharmaceutical compositions comprising the same.06-21-2012
20120238631COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES - The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.09-20-2012
201301504491-AMINO-ALKYLCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES - The present invention relates to the treatment of an individual afflicted with inflammatory skin diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.06-13-2013
201301581241-AMINO-ALKYLCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF MAST CELL MEDIATED DISEASES - The present invention relates to the treatment of an individual afflicted with mast cell mediated diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.06-20-2013
20130165522GEL FORMULATIONS FOR THE TOPICAL USE OF 1-AMINO-ALKYLCYCLOHEXANE DERIVATIVES - This invention provides a pharmaceutical composition for topical application to the skin of a patient in need of, comprising neramexane or a pharmaceutically acceptable salt thereof, and at least one gel forming agent for the treatment or prevention of inflammatory skin diseases such as impetigo contagiosa, acne, rosacea, eczema, atopic dermatitis, contact dermatitis, seborrheic dermatitis, psoriasis, and/or oily skin. The at least one gel forming agent comprises polymers with neutral and/or positively charged polymer backbones.06-27-2013
201401072121-AMINO-ALKYLCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF MAST CELL MEDIATED DISEASES - The present invention relates to the treatment of an individual afflicted with mast cell mediated diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.04-17-2014
20140350114COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES - The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.11-27-2014
20150018425TITRATION PACKAGE FOR NERAMEXANE AND ITS USE IN THE TREATMENT OF AN INNER EAR DISORDER - The present invention relates to a titration scheme for the administration of a 1-amino-alkylcyclohexane derivative which allows for quick attainment of an effective dose of a 1-amino-alkylcyclohexane derivative while minimizing side effects. The present invention further relates to a titration package for providing a 1-amino-alkylcyclohexane derivative (e.g., neramexane or a pharmaceutically acceptable salt thereof) in at least two different dosages. The present titration scheme/titration package may be useful in the treatment of various diseases, including tinnitus.01-15-2015

Patent applications in class Nitrogen containing other than solely as a nitrogen in an inorganic ion of an addition salt, a nitro or a nitroso DOAI

Patent applications in all subclasses Nitrogen containing other than solely as a nitrogen in an inorganic ion of an addition salt, a nitro or a nitroso DOAI

Website © 2025 Advameg, Inc.